Wacker Biosolutions to focus on biotechnology
Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology
Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.
The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.
Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.
"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.
Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.
You may also like
Manufacturing
LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener
Read moreFollowing the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
Trending Articles
You may also like
Manufacturing
LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener
Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
Manufacturing
Particology joins £8.2m consortium to drive greener, more efficient medicines manufacturing
The company has been selected for Innovate UK’s £54m Sustainable Medicines Manufacturing Innovation Programme, leading crystallisation research to cut waste, reduce energy use and accelerate next-generation pharmaceutical production
Manufacturing
Valve diagnostics: providing new insights for medical and lab applications
Across a range of medical and laboratory applications, confirmation of liquid flow status is critical, but integrating sensors or electronics to check the performance of functions like valve switching adds design complexity
Manufacturing
Marchesini Group and AST announce strategic partnership to strengthen aseptic production capacity and expand global market presence
Marchesini Group, a leader in pharmaceutical packaging machinery, and AST, a US leader in the drug product manufacturing industry, have entered a strategic partnership that combines the expertise, technologies, and global reach of two highly respected industry leaders